UNSPSC 51142538: Rotigotine

This classification denotes a dopamine agonist with the molecular formula C19H25NOS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 87T4T8BO2E, chemically known as 6-(propyl(2-(2-thienyl)ethyl)amino)-5,6,7,8-tetrahydro-1-naphthalenol but generally known as rotigotine, which bears US NIH Compound Identifier 57537. European Medicines Agency schedules Rotigotine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21254.

UNSPSC 51142538 Rotigotine is a Commodity code that nominally identifies a specific pharmaceutical active ingredient, but recent state and local opportunities tagged under this code show little direct connection to rotigotine procurement itself. Instead, the recent activity spans broader pharmaceutical and medical-product sourcing across health departments, county health systems, and state health agencies. The work actually being solicited includes naloxone and drug-deactivation-system purchases for community health response, direct-to-manufacturer prescription programs for state pharmacy benefit administration, and generic multi-source pharmaceutical and over-the-counter product supply agreements for state and local government facilities. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and state-level cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The mix reflects both standalone county procurement and participation in multi-state cooperative vehicles.

Geographic activity centers on Florida, Texas, and Minnesota, with MMCAP's cooperative extending to Oregon and other participating jurisdictions. Representative recent opportunities include Seminole County's IFB for naloxone and drug-deactivation systems (IFB60459723LAS, due July 26, 2026), seeking 1,900 units of naloxone and 800 safe drug-deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford; the Texas HHS Commission's Request for Information (RFI HHS0017013, posted April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program; and MMCAP's multi-state RFP (S1070000015802, due March 26, 2026) to establish contracts for generic pharmaceuticals and OTC products distributed through authorized wholesalers including AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson, with awards effective July 1, 2026. The code shows sparse direct rotigotine activity; recent procurement focuses on broader pharmaceutical supply, community-health response products, and state pharmacy benefit program logistics.